Prosecution Insights
Last updated: August 16, 2026

Atai Therapeutics, Inc.

4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days

Portfolio Summary

4
Total Pending OAs
3
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
4
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only2 (50%)
Double-patenting + other2 (50%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

3
Life Sciences
75% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
1
Mechanical / Eng
25% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HEASLEY, MEGHAN CHRISTINE 1 76.6% +34.8%
SAEED, KAMAL A 1 83.8% +9.6%
BURGESS, JOSEPH D 1 39.7% +35.9%
CHENG, KAREN 1 76.3% +27.1%

Quick Wins (1)

Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18532940 SULFOXIMINE ACTIVATORS OF SEROTONIN RECEPTORS SAEED, KAMAL A

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18504056 SYSTEMS, DEVICES, AND METHODS FOR EVENT-BASED KNOWLEDGE REASONING SYSTEMS USING ACTIVE AND PASSIVE SENSORS FOR PATIENT MONITORING AND FEEDBACK BURGESS, JOSEPH D 30d overdue
18541172 PRODRUGS OF DIMETHYLTRYPTAMINE AND DERIVATIVES THEREOF HEASLEY, MEGHAN CHRISTINE
18192603 COMPOSITIONS AND METHODS FOR TREATING HEADACHE OR FACIAL PAIN CHENG, KAREN

Top Art Units

Art UnitApps
1626 2
3685 1
1623 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18541172 PRODRUGS OF DIMETHYLTRYPTAMINE AND DERIVATIVES THEREOF HEASLEY, MEGHAN CHRISTINE 1626 §102DP Non-Final OA Pending May 01, 2024
18532940 SULFOXIMINE ACTIVATORS OF SEROTONIN RECEPTORS SAEED, KAMAL A 1626 DPOther Non-Final OA Pending Dec 07, 2023
18504056 SYSTEMS, DEVICES, AND METHODS FOR EVENT-BASED KNOWLEDGE REASONING SYSTEMS USING ACTIVE AND PASSIVE SENSORS FOR PATIENT MONITORING AND FEEDBACK BURGESS, JOSEPH D 3685 §103 Final Rejection 30d overdue Pending Nov 07, 2023
18192603 COMPOSITIONS AND METHODS FOR TREATING HEADACHE OR FACIAL PAIN CHENG, KAREN 1623 §103 Non-Final OA Pending Mar 29, 2023

Managing Atai Therapeutics, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month